GlassScriptPhysician profile
Judith Vanwhervin
NPI 1235726134
$6,802.22
in general payments reported to CMS, 2019-2025
24 companies · $1,531 in 2025
The $1,531 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $372 · 2022: $894 · 2023: $2,880 · 2024: $1,126 · 2025: $1,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,536.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,690.32 | 2022-2025 | Lynparza, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $696.80 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $485.38 | 2021-2023 | Lunsumio |
| Genzyme Corporation | $446.14 | 2021-2025 | |
| Janssen Biotech, INC. | $404.34 | 2022-2024 | Erleada, Tecvayli, Darzalex |
| Gilead Sciences, INC. | $384.18 | 2024-2025 | Livdelzi, Epclusa, Trodelvy |
| Jazz Pharmaceuticals INC. | $366.64 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $254.63 | 2023-2024 | Opdivo |
| Abiomed | $228.52 | 2025 | |
| Eisai INC. | $228.19 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $212.48 | 2023-2024 | Purified Cortrophin Gel |
| Seagen INC. | $205.73 | 2023 | Tivdak, Tukysa |
| Medtronic, INC. | $146.44 | 2025 | Symplicity G3 |
| Novo Nordisk INC | $129.46 | 2023-2025 | Rybelsus |
| Stemline Therapeutics INC. | $125.62 | 2023 | Orserdu |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $125.00 | 2025 | |
| Pfizer INC. | $124.99 | 2024 | |
| Amgen INC. | $117.12 | 2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.59 | 2023-2024 | Ofev |
| Teva Pharmaceuticals USA, INC. | $100.00 | 2025 | |
| Mylan Specialty L.P. | $87.97 | 2023 | Yupelri |
| Celgene Corporation | $81.24 | 2021 | |
| Reprise Biomedical, INC. | $25.30 | 2025 | Miro3d |
| Integra Lifesciences Corporation | $20.14 | 2024 | Tcc-Ez |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Vanwhervin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.